PPT-ENDURANCE-4: Efficacy and Safety of Glecaprevir/Pibrentasvi

Next Generation DirectActing Antivirals Geographic Distribution of Enrolled Patients. october. 2015. N. “ENDURANCE”. Defining the term:. “It . is a deliberate act of withstanding the . spiritual, mental. , . physical, and emotional . challenges that are embedded in the believer’s new life in Christ. 1. 1. http://www.accessdata.fda.gov/cdrh_docs/pdf/P980048b.pdf. The . views and opinions expressed in the following PowerPoint slides are those of . the individual . presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, . Explore different fitness training methods. Flexibility training. Strength, Muscular Endurance and Power training. Aerobic Endurance training. Speed training. Strength, Muscular . E. ndurance and Power training . Field Program Assistant. IR-4 Western Region. . Western Region Ornamental Program. Overview of the program. Participation. Specifics of 2010 and 2011 research. Strengths and challenges. . WR Ornamental Program 2010-11. Objectives:. . The student will understand the principle of muscular strength fitness.. The student will recognize the principle of muscular endurance.. Each student will comprehend the FITT principles of muscular strength/muscular endurance i.e. frequency, intensity, time, type.. Open label. ≥ . 18 years. HCV genotype 4, 5 or 6. BMI ≥ 18 kg/m. 2. Treatment-naïve or treatment-experienced with IFN or PEG-IFN . +.  RBV or SOF + RBV . +.  PEG-IFN. No cirrhosis **. Creatinine clearance ≥ 50 mL/min. NASPE Standards: 2,4. 8.1 – Muscular Endurance Basics. 4 Objectives:. Tell the differences among muscular endurance, cardiovascular fitness, and muscular strength.. Describe benefits of good muscular endurance. ≥ 18 years. HCV genotype 3. Treatment-naïve . HCV RNA > 1 000 IU/mL. No cirrhosis **. No HBV co-infection. No HIV co-infection. ENDURANCE-3 Study: . glecaprevir. /. pibrentasvir. . vs SOF DCV in genotype 3 without cirrhosis. Emily Ellsworth, . PharmD. & Janna Hawthorne, . PharmD. UAMS College of Pharmacy. Objectives:. Explain . the pathophysiological rationale for the off-label utilization of six selected medications: . Alfonso Iorio, MD, PhD. Health Information Research Unit & Hemophilia Program. McMaster. University. Canada. Alfonso Iorio. Baxter . (Bayer, . Biogen. Idec, . NovoNordisk. , Pfizer . - No conflicts). List 3 kinds of physical activity that you participate in.. What is your favorite form of physical activity?. What does FITT stand for?. What does SMART stand for?. What are the components of fitness?. Consultant Pediatrcian,Pedicare, Ratu Road,rch_sssidana@rediffmail.com. Alleviation of Pain Associated in HCV GT 1 & Prior DAA Treatment. MAGELLAN-1 (Part 1). Phase . 2 . Treatment-Experienced. Source: . Poordad. . F, et al. Hepatology. 2017;66:389-97. . Source: Poordad F, et al. Hepatology. 2017;66:389-97. . double-blind, placebo-controlled study with open-label extension. Atul Deodhar, MD. Oregon Health & Science University. Portland, OR, USA. Key message. Upadacitinib – a JAK1 inhibitor – showed sustained and consistent efficacy over 1 year in AS patients..